{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:58:54Z","timestamp":1787169534428,"version":"build-2736575974"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,3]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>More and more cases of myelin oligodendrocyte glycoprotein (MOG) antibody are being diagnosed with the availability of laboratory tests helping us to know the differing patterns from AQP-4 antibody disease and we need to understand the natural course, treatment, and prognosis in a better way.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>Neuromyelitis optica spectrum disorder (NMOSD) and anti-MOG syndromes are immune-mediated inflammatory demyelinating conditions of the central nervous system (CNS) that mainly involve the optic nerves and the spinal cord. We conducted this study to compare demographic, clinical, laboratory, and radiological features of AQP-4 antibody and MOG antibody positive patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A single-centre retrospective observational study from a large tertiary care university centre of Northwest India conducted during 2019--2021. We screened all patients presenting with acute CNS demyelinating attacks and recruited total 47 patients of which 25 were positive for AQP4 antibody and 22 were positive for MOG antibody. No patient tested positive for both antibodies. Data were collected using a standardized format including demographic, clinical, laboratory, and neuroimaging data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>In our study, total 47 patients were included, amongst which 25 patients were AQP4 antibody and 22 patients were MOG antibody positive. Though there was no gender preponderance, pediatric patients were more frequently affected in MOG antibody positive group. In AQP-4 antibody positive patients, myelitis was most common presenting clinical feature followed by optic neuritis (ON), simultaneous ON with myelitis, and brainstem syndrome. In MOG antibody positive group, myelitis was the commonest phenotype followed by ON, brainstem syndrome, and cerebral syndrome. The neuroimaging revealed involvement of medulla mainly area postrema, cervicodorsal spinal cord and extension of cervical lesion up to brainstem more commonly in AQP4 antibody group, on the other hand involvement of upper brainstem (midbrain and pons), cortex, and conus was more common in MOG antibody group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>We have made an attempt to find differentiating features in AQP-4 vs. MOG antibody positive cases but they were of no statistically significance value as the numbers were small. Further larger studies may prove helpful in planning better strategies in two groups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/aian.aian_860_21","type":"journal-article","created":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T02:17:51Z","timestamp":1644200271000},"page":"246-255","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Comparison of Clinical and Radiological Features of Aquaporin4 (AQP-4) Antibody Positive Neuromyelitis Optica Spectrum Disorder (NMOSD) and Anti Myelin Oligodendrocyte Glycoprotein (Anti-MOG) Syndrome-Our Experience from Northwest India"],"prefix":"10.4103","volume":"25","author":[{"given":"Rajendra Singh","family":"Jain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sourabh","family":"Murarka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Vyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhawna","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trilochan","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamlesh","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yavnika","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavya","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitesh","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shankar","family":"Tejwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-19-20240828","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1001\/archneurol.2011.216","article-title":"Failure of natalizumab to prevent relapses in neuromyelitis optica","volume":"69","author":"Kleiter","year":"2012","journal-title":"Arch Neurol"},{"key":"R2-19-20240828","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1352458511431973","article-title":"Development of extensive brain lesions following fingolimod (fty720) treatment in a patient with neuromyelitis optica spectrum disorder","volume":"18","author":"Min","year":"2012","journal-title":"Mult Scler"},{"key":"R3-19-20240828","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00415-013-7169-7","article-title":"Update on the diagnosis and treatment of neuromyelitis optica: Recommendations of the neuromyelitis optica study group (nemos)","volume":"261","author":"Trebst","year":"2014","journal-title":"J Neurol"},{"key":"R4-19-20240828","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/ene.12898","article-title":"Neuromyelitis optica spectrum disorders: Comparison of clinical and magnetic resonance imaging characteristics of aqp4-igg versus mog-igg seropositive cases in the netherlands","volume":"23","author":"van Pelt","year":"2016","journal-title":"Eur J Neurol"},{"key":"R5-19-20240828","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.msard.2018.07.025","article-title":"Mog antibody disease: A review of mog antibody seropositive neuromyelitis optica spectrum disorder","volume":"25","author":"Narayan","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"R6-19-20240828","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1177\/1352458515622986","article-title":"Screening for mog-igg and 27 other anti-glial and anti-neuronal autoantibodies in \u2018pattern ii multiple sclerosis\u2019 and brain biopsy findings in a mog-igg-positive case","volume":"22","author":"Jarius","year":"2016","journal-title":"Mult Scler"},{"key":"R7-19-20240828","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/acn3.164","article-title":"Histopathology and clinical course of mog-antibody-associated encephalomyelitis","volume":"2","author":"Spadaro","year":"2015","journal-title":"Ann Clin Transl Neurol"},{"key":"R8-19-20240828","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1007\/s00401-013-1116-7","article-title":"Presence of six different lesion types suggests diverse mechanisms of tissue injury in neuromyelitis optica","volume":"125","author":"Misu","year":"2013","journal-title":"Acta Neuropathol"},{"key":"R9-19-20240828","doi-asserted-by":"crossref","first-page":"e60","DOI":"10.1212\/NXI.0000000000000060","article-title":"Mog antibody-associated diseases","volume":"2","author":"Reindl","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R10-19-20240828","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1212\/NXI.0000000000000175","article-title":"Fulminant demyelinating encephalomyelitis: Insights from antibody studies and neuropathology","volume":"2","author":"Dipauli","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"R11-19-20240828","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/1742-2094-8-184","article-title":"Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders","volume":"8","author":"Mader","year":"2011","journal-title":"J Neuroinflammation"},{"key":"R12-19-20240828","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1212\/WNL.0000000000000101","article-title":"Distinction between MOG antibodypositive and AQP4 antibodypositive NMO spectrum disorders","volume":"82","author":"Sato","year":"2014","journal-title":"Neurology"},{"key":"R13-19-20240828","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1001\/jamaneurol.2013.5857","article-title":"Neuromyelitis optica spectrum disorders with aquaporin4 and myelinoligodendrocyte glycoprotein antibodies a comparative study","volume":"71","author":"Kitley","year":"2014","journal-title":"JAMA Neurol"},{"key":"R14-19-20240828","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1177\/1352458514555785","article-title":"Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease","volume":"21","author":"H\u00f6ftberger","year":"2015","journal-title":"Mult Scler"},{"key":"R15-19-20240828","first-page":"14","article-title":"MOGIgG in NMO and related disorders: A multicenter study of 50 patients.Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and longterm outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflammation"},{"key":"R16-19-20240828","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1007\/s00415-015-7983-1","article-title":"Isolated new onset \u2018atypical\u2019 optic neuritis in the NMO clinic: Serum antibodies, prognoses and diagnoses at followup","volume":"263","author":"Piccolo","year":"2016","journal-title":"J Neurol"},{"key":"R17-19-20240828","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/NXI.0000000000000322","article-title":"MOG antibodypositive, benign, unilateral, cerebral cortical encephalitis with epilepsy","volume":"4","author":"Ogawa","year":"2017","journal-title":"Neurol Neuroimmunol NeuroInflammation"},{"key":"R18-19-20240828","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jamaneurol.2017.3196","article-title":"Seizures and encephalitis in myelin oligodendrocyte glycoprotein igg disease vs aquaporin 4 IgG disease","volume":"75","author":"Hamid","year":"2018","journal-title":"JAMA Neurol"},{"key":"R19-19-20240828","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"key":"R20-19-20240828","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1177\/1352458513484547","article-title":"International pediatric multiple sclerosis study group criteria for pediatric multiple sclerosis and immunemediated central nervous system demyelinating disorders: Revisions to the 2007 definitions","volume":"19","author":"Krupp","year":"2013","journal-title":"Mult Scler"},{"key":"R21-19-20240828","first-page":"e1858","article-title":"Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR study","volume":"90","author":"CoboCalvo","year":"2018","journal-title":"Neurology"},{"key":"R22-19-20240828","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.4103\/0028-3886.294831","article-title":"Myelin oligodendrocyte glycoprotein (MOG) antibody-associated CNS demyelination: Clinical spectrum and comparison with aquaporin-4 antibody positive neuromyelitis optica spectrum disorder","volume":"68","author":"Ojha","year":"2020","journal-title":"Neurol India"},{"key":"R23-19-20240828","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1212\/WNL.0b013e318248dec1","article-title":"Serologic diagnosis of NMO: A multicenter comparison of aquaporin-4-IgG assays","volume":"78","author":"Waters","year":"2012","journal-title":"Neurology"},{"key":"R24-19-20240828","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1136\/jnnp-2012-302310","article-title":"Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders","volume":"84","author":"Jacob","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R25-19-20240828","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1093\/brain\/awx276","article-title":"Clinical presentation and prognosis in MOGantibody disease: A UK study","volume":"140","author":"Jurynczyk","year":"2017","journal-title":"Brain"},{"key":"R26-19-20240828","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1212\/WNL.0000000000004312","article-title":"Prognostic relevance of MOG antibodies in children with an acquired demyelinating syndrome","volume":"89","author":"Hennes","year":"2017","journal-title":"Neurology"},{"key":"R27-19-20240828","doi-asserted-by":"crossref","first-page":"69","DOI":"10.4103\/aian.AIAN_627_19","article-title":"Myelin oligodendrocyte glycoprotein (MOG)-IgG associated demyelinating disease: Our experience with this distinct syndrome","volume":"24","author":"Pujari","year":"2021","journal-title":"Ann Indian Acad Neurol"},{"key":"R28-19-20240828","doi-asserted-by":"crossref","first-page":"505","DOI":"10.4103\/0972-2327.192389","article-title":"Serological markers associated with neuromyelitis optica spectrum disorders in South India","volume":"19","author":"Pandit","year":"2016","journal-title":"Ann Indian Acad Neurol"},{"key":"R29-19-20240828","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4103\/0972-2327.128559","article-title":"A clinical and radiological profile of neuromyelitis optica and spectrum disorders in an Indian cohort","volume":"17","author":"Barhate","year":"2014","journal-title":"Ann Indian Acad Neurol"}],"container-title":["Annals of Indian Academy of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aian.aian_860_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T19:09:51Z","timestamp":1787166591000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aian.aian_860_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/aian.aian_860_21","relation":{},"ISSN":["0972-2327"],"issn-type":[{"value":"0972-2327","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]}}}